A recent survey commissioned by our company across more than 50 small, mid-sized, and large biopharmaceutical companies worldwide, shed light on the key reasons why biotechs outsource their early biologic development and manufacturing to a CDMO. In this 20-min panel discussion, members of our End-to-End Solutions team, part of the BioReliance® portfolio, will offer their perspectives on what we heard from respondents.
We discuss major hurdles biotechs mentioned and how a customer-centric CDMO partnership can help overcome these, dismissing the idea of one-size-fits-all.
In this webinar, you will learn about:
Magali Toueille, Ph.D.
Downstream Process Development Manager
Magali Toueille, Ph.D. is a downstream process development manager at our End-to-End Biodevelopment Center Martillac, France. She leads downstream process development activities for client projects as well as internal projects aimed at continuously optimizing the performance of our developments. Magali holds a Ph.D. in Biological Science.
Magali has held several research positions in France and Switzerland, and she was a senior manager, chromatography applications at Pall Life Sciences. She also held the position of head of downstream process development and preclinical production at Genethon for 5 years. Magali holds a Ph.D. in biological science.
Celine Raymond, Ph.D.
Upstream Process Development Manager
Céline Raymond, Ph.D. is an upstream process development manager at our End-to-End Biodevelopment Center Martillac, France. She leads upstream process development activities for client projects as well as internal projects aimed at continuously optimizing the performance of our developments.
After studying chemical engineering and biochemistry in France and Canada, Céline joined our End-to-End Biodevelopment Center Martillac in 2015 as upstream scientist before taking on the role as the head of the department in 2019. Celine holds a Ph.D. in biochemistry.
To continue reading please sign in or create an account.Don't Have An Account?